Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On July 14, 2026, the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") of Cocrystal Pharma, Inc. (the "Company") was held. At the 2026 Annual Meeting, the Company's stockholders voted on (i) the election of five members of the Company's Board of Directors (Proposal 1); (ii) ratification of the appointment of Weinberg & Company as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 2); and (iii) approval of an adjournment of the 2026 Annual Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at the time of the 2026 Annual Meeting to approve any of the proposals presented for a vote at the 2026 Annual Meeting (Proposal 3), all as described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on May 27, 2026.

Set forth below are the voting results on each matter submitted to the stockholders at the 2026 Annual Meeting.

Proposal 1. The Company's stockholders voted to elect the following five individuals as directors to hold office until the next annual meeting of stockholders and until his or her successor is duly elected and qualified:

Proposal 2. The Company's stockholders voted to ratify the appointment of Weinberg & Company as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

As there were sufficient votes to approve Proposals 1 and 2, Proposal 3 was moot.